KBC Group NV boosted its stake in shares of DaVita Inc. (NYSE:DVA – Get Rating) by 25.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 46,888 shares of the company’s stock after acquiring an additional 9,568 shares during the quarter. KBC Group NV’s holdings in DaVita were worth $5,304,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors also recently bought and sold shares of the stock. Gates Capital Management Inc. boosted its holdings in DaVita by 6.9% during the 4th quarter. Gates Capital Management Inc. now owns 1,601,450 shares of the company’s stock valued at $182,181,000 after acquiring an additional 103,916 shares during the period. Geode Capital Management LLC boosted its holdings in DaVita by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 1,186,053 shares of the company’s stock valued at $134,555,000 after acquiring an additional 10,143 shares during the period. Todd Asset Management LLC boosted its holdings in DaVita by 6.7% during the 1st quarter. Todd Asset Management LLC now owns 487,434 shares of the company’s stock valued at $55,133,000 after acquiring an additional 30,746 shares during the period. Iron Triangle Partners LP purchased a new stake in DaVita in the 4th quarter worth approximately $51,192,000. Finally, Speece Thorson Capital Group Inc. lifted its holdings in DaVita by 11.6% in the 4th quarter. Speece Thorson Capital Group Inc. now owns 186,774 shares of the company’s stock worth $21,247,000 after buying an additional 19,341 shares during the period. 87.47% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on the company. Bank of America dropped their price objective on DaVita from $110.00 to $90.00 and set an “underperform” rating for the company in a report on Tuesday, June 21st. Barclays dropped their price objective on DaVita from $128.00 to $103.00 and set an “equal weight” rating for the company in a report on Thursday. StockNews.com cut DaVita from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 5th. Truist Financial decreased their target price on DaVita from $110.00 to $90.00 and set a “hold” rating for the company in a research report on Wednesday, June 22nd. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on DaVita from $150.00 to $97.00 and set a “buy” rating for the company in a research report on Tuesday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $106.00.
Insider Activity at DaVita
DaVita Stock Up 0.4 %
DVA stock opened at $85.68 on Friday. DaVita Inc. has a twelve month low of $74.97 and a twelve month high of $134.47. The company has a quick ratio of 1.25, a current ratio of 1.41 and a debt-to-equity ratio of 11.69. The firm has a market cap of $7.82 billion, a PE ratio of 10.63, a price-to-earnings-growth ratio of 1.32 and a beta of 1.16. The business has a 50 day moving average of $86.51 and a 200 day moving average of $102.22.
DaVita (NYSE:DVA – Get Rating) last posted its quarterly earnings data on Monday, August 1st. The company reported $2.30 earnings per share for the quarter, beating analysts’ consensus estimates of $2.09 by $0.21. DaVita had a return on equity of 84.69% and a net margin of 7.17%. The company had revenue of $2.93 billion during the quarter, compared to analyst estimates of $2.93 billion. During the same quarter last year, the company earned $2.64 EPS. The firm’s revenue for the quarter was up .4% on a year-over-year basis. On average, research analysts forecast that DaVita Inc. will post 7.68 EPS for the current fiscal year.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
- Get a free copy of the StockNews.com research report on DaVita (DVA)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.